英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
48219查看　48219　在百度字典中的解释百度英翻中〔查看〕
48219查看　48219　在Google字典中的解释Google英翻中〔查看〕
48219查看　48219　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Phase II Study of Ponatinib in Advanced Gastrointestinal . . . - PubMed
    Purpose: The purpose of this study is to evaluate ponatinib for advanced gastrointestinal stromal tumors (GIST) Patients and methods: This single-arm phase II trial enrolled patients with metastatic and or unresectable GIST with failure of prior tyrosine kinase inhibitor (TKI) treatment into two cohorts based on presence or absence of KIT exon 11 (ex11) primary mutations
  • Ponatinib (Iclusig) | GIST Support International
    Phase II trial for GIST A Phase 2 Trial of Ponatinib in Patients With Metastatic and or Unresectable Gastrointestinal Stromal Tumor (NCT01874665) Clinical trial information: NCT01874665 Patients who enrolled in this trial had failed at least one prior TKI therapy
  • Drugs in the GIST Field (Therapeutic Targets and Clinical Trial Staging . . .
    Ponatinib (AP-24534, Iclusig, INCB-84344, ponatinib hydrochloride) is a TKI targeted to the BCR activator of RhoGEF + GTPase, ABL, FLT1 (VEGFR1), The first clinical trial of medicines related to GIST began in 1997 The number increased significantly from 1997 to 2008 and remained stable from 2008 to 2021 (Fig 2) Combined with the previous
  • Clinical Trial: NCT03171389 - My Cancer Genome
    This is a non-randomized, open-label, multicenter phase 2 study to evaluate the efficacy and safety of ponatinib in patients with metastatic and or unresectable GIST after prior failure or intolerability of imatinib Patients will be enrolled into 1 of 2 cohorts based on absence (Cohort A) or presence (Cohort B) of KIT exon 13 resistance mutations as measured by liquid biopsy
  • GIST Clinical Trial - A Phase 2 Trial of Ponatinib in Participants With
    A Phase 2 Trial of Ponatinib in Participants With Metastatic and or Unresectable Gastrointestinal Stromal Tumor — GIST GIST Clinical Trial Official title: Phase 2 Trial of Ponatinib in Patients With Metastatic and or Unresectable Gastrointestinal Stromal Tumor Following Failure of Prior Tyrosine Kinase Inhibitor Therapy
  • Ponatinib efficacy and safety in patients (pts) with advanced . . .
    Background: The oral TKI ponatinib has potent pre-clinical activity against mutant KIT and PDGFRA, including clinically relevant mutants resistant to available TKIs We hypothesized that ponatinib might be effective in GIST after prior TKI treatment failure Methods: This phase 2, single-arm study (NCT01874665) evaluated efficacy and safety of ponatinib 45 mg qd in advanced GIST after TKI
  • Phase 2 Study of Ponatinib in Patients (Pts) with Advanced . . .
    Methods: This phase 2 single arm trial evaluated efficacy and safety of ponatinib at 45 mg qd in advanced GIST pts after failure of prior TKI therapies Pts were enrolled in Cohorts based on the presence (A) or absence (B) of KIT exon 11 mutations Primary end point: clinical benefit rate (CBR=CR+PR+SD at 16 wks) by modified RECIST 1 1 in Cohort A Secondary end points: CBR in Cohort B and
  • Ponatinib in GIST - Clinical Trials Registry - ICH GCP
    Clinical Trial NCT01874665 to evaluate the efficacy and safety of ponatinib in participants with metastatic and or unresectable gastrointestinal stromal tumor (GIST) following failure of prior tyrosine kinase inhibitor (TKI) therapy This is a non-randomized, open label, multi-center phase 2 study to evaluate the efficacy and safety of
  • Treatment of Metastatic Gastrointestinal Stromal Tumors (GIST): A Focus . . .
    In a phase III clinical trial with the novel TKI avapritinib in patients with GIST harboring PDGFRA exon 18 mutations, the median age of patients was 64 years (range 29–90) Of the participants, 56% were exposed for ≥ 6 months and 44% were exposed for > 1 year The safety of ponatinib in patients with GIST was assessed in the phase II
  • Lower-dosing ponatinib in pre-treated GIST: Results of the POETIG phase . . .
    Clinical trial information: NCT03171389 This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I This abstract does not include a full text component Lower-dosing ponatinib in pre-treated GIST: Results of the POETIG phase II trial JCO 38, 11536-11536 (2020)





中文字典-英文字典  2005-2009